Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ )

0.3501 +0.0101 (+2.97%)
Streaming Delayed Price Updated: 11:30 AM EDT, Aug 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
From Mainz BioMed NV
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Crude Oil Gains Over 1%; US Budget Deficit Narrows For October
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining around 50 points on Monday. The Dow traded up 0.16% to 34,337.33 while the NASDAQ fell 0.11% to 13,783.41. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Mainz Biomed (MYNZ) Stock Is Getting Hammered
Mainz Biomed NV (NASDAQ: MYNZ) shares are trading lower by 46% to $1.21 during Monday's session has entered a securities purchase agreement with institutional investors to raise $5 million through a 
Via Benzinga
Dow Surges 100 Points; Tenax Therapeutics Shares Spike Higher
U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining around 100 points on Monday. The Dow traded up 0.33% to 34,397 while the NASDAQ fell 0.06% to 13,790. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Fall; Tyson Foods Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 100 points on Monday. Following the market opening Monday, the Dow traded down 0.08% to 34,254.53 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
Exposures US Equities
Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Partners With Liquid Biosciences In Exclusive Relationship To Harness The Power Of Artificial Intelligence (AI) To Develop Next-Generation Colorectal Screening Test
The integration of Artificial Intelligence (AI) in biotechnology is rapidly gaining momentum, revolutionizing the field of life sciences. AI technologies, such as machine learning and deep learning... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
Collaboration to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processing 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed’s (NASDAQ: MYNZ) ColoFuture Study Reveals “Groundbreaking Results”: ColoAlert® Raises The Bar For Colorectal Cancer Detection
--News Direct-- 
Via News Direct
Topics Death
Exposures Death
AI Meets Oncology! Mainz Biomed Inks Pact With Liquid Biosciences To Develop Next-Gen Colorectal Cancer Screening Test
Mainz Biomed N.V. (NASDAQ: MYNZ) inked a pact with Liquid Biosciences, a bio-analytics company leveraging its proprietary AI analysis technology platform (EMERGE), to enhance the  
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioNTech Shifted Its Focus To Innovative Oncology And Mainz Biomed Announced A Showcasing Of Its Revolutionary Colorectal Cancer Detection Test
On November 6th, BioNTech SE (NASADQ: SE) who partnered with Pfizer Inc (NYSE: PFE) in the making of a blockbuster COVID-19 vaccine, posted a surprise earnings with its latest quarterly report. 
Via Benzinga
Exposures COVID-19
Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed's (NASDAQ: MYNZ) ColoFuture Study Reveals "Groundbreaking Results": ColoAlert® Raises The Bar For Colorectal Cancer Detection
Throughout the world, colorectal cancer has emerged as the third most prevalent form of cancer. 
Via Benzinga
Splunk Layoffs 2023: What to Know About the Latest SPLK Job Cuts
Splunk layoffs are on the way for 7% of the cybersecurity company's global employees as it continues a restructuring plan. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Why Is WeWork (WE) Stock Down 38% Today?
WeWork stock is falling on Wednesday as investors in WE shares react to reports that the company is considering a bankruptcy filing. 
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
Why Is Paycom Software (PAYC) Stock Down 39% Today?
Paycom Software stock is falling hard on Wednesday as investors in PAYC go over the company's mixed earnings report for Q3 2023! 
Via InvestorPlace
Why Is Mainz Biomed (MYNZ) Stock Moving Today?
Mainz Biomed stock is on the move Wednesday as investors in MYNZ react to results from a colorectal cancer screening test campaign. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today! 
Via InvestorPlace
Today's Pharma Tales Of Loss And Success: Pfizer Swings To A Quarterly Loss And Mainz Biomed Reports Positive Interim Screening Campaign Results
As it struggles to navigate the rapid decline of its Covid-19 fame, Pfizer Inc (NYSE: PFE) reported a quarterly loss for the third quarter. 
Via Benzinga
Exposures COVID-19
Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
Almost half of Zöller-KipperGmbH’s employees in Germany participated in the screening program so far using ColoAlert®, Mainz Biomed’s user-friendly, at-home colorectal cancer (CRC) screening test 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
From Mainz BioMed NV
Via GlobeNewswire
Johnson & Johnson Was Saved By Its Focus On MedTech And Innovative Medicine
Johnson & Johnson (NYSE: JNJ) reported its third quarter results that topped Wall Street’s expectations while also lifting its full year guidance fueled by a strong performance of its pharmaceutical... 
Via Benzinga
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
Mainz Biomed team members will be available throughout the event at the Company’s booth located in Hall C, Stand C3-92 
From Mainz BioMed NV
Via GlobeNewswire
Big Pharma Could Transform Into BioTech Pharma
As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall... 
Via Benzinga
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Continues To Transform Early Cancer Detection Across The Globe
While Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) are making great progress in cancer treatments, the importance of early detection in combating this disease cannot be overstated. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.